| iniparib (BSI 201) / Sanofi |
NCT00540358: A Phase 2 Trial of Standard Chemotherapy, With or Without BSI-201, in Patients With Triple Negative Metastatic Breast Cancer |
|
|
| Completed | 2 | 123 | US | gemcitabine/carboplatin, iniparib, BSI-201, SAR240550 | Sanofi, BiPar Sciences | Breast Cancer | 11/09 | 06/10 | | |
|
|
|
|
NCT01045304 / 2009-016091-80: Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer |
|
|
| Completed | 2 | 163 | Europe, RoW | Iniparib, SAR240550, BSI-201, Gemcitabine, Carboplatin | Sanofi | Breast Cancer, Metastatic | 03/11 | 11/12 | | |
|
|
|
|
NCT00813956: A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer |
|
|
| Completed | 2 | 80 | US | gemcitabine plus carboplatin plus BSI-201 | Sanofi, Breast Cancer Research Foundation | Triple Negative Breast Cancer | 10/12 | 10/12 | | |
|
|
|
|
NCT01173497: A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis |
|
|
| Completed | 2 | 44 | US | INIPARIB + irinotecan | Sanofi, UNC Lineberger Comprehensive Cancer Center | Estrogen Receptor Negative (ER-Negative) Breast Cancer, Progesterone Receptor Negative (PR-Negative) Breast Cancer, Human Epidermal Growth Factor Receptor 2 Negative (HER2-Negative) Breast Cancer, Brain Metastases | 10/12 | 07/13 | | |
|
|
| Completed | 2 | 141 | Europe | paclitaxel, Iniparib (SAR2405550 -BSI-201) | Sanofi, SOLTI Breast Cancer Research Group | Breast Cancer Female | 10/12 | 02/17 | | |
|
